Vanessa Williams ties Mounjaro use to menopause

Vanessa Williams has become the latest celebrity to speak publicly about using a GLP-1 drug, telling Hello! magazine that she takes Mounjaro amid menopause-related changes to her body ^[1]. Williams, who turned 60, said the decision was tied to wanting to stay healthy and feel her best as she aged, not to chase a smaller size ^[1].

"It's a game-changer," Williams said. "When I turned 60, I was like: 'I want to be here for a long time, and I want to look my best. So what am I going to do?'" ^[1] She described her fifties as difficult, saying she started perimenopause in her late forties but that things shifted sharply around age 51. "You feel out of control because you're working out the same way, eating the same, and your body is not reacting the way it used to," she said ^[1].

Mounjaro's active ingredient is tirzepatide, and the drug is approved by regulators to treat type 2 diabetes; it is not specifically approved to treat menopause symptoms ^[1]. Its use for weight-related concerns during midlife, including by public figures, has largely been described in interviews rather than in labeled indications ^[1].

Williams joins a growing list of women over 50 who have talked openly about GLP-1 use in recent years, including Rosie O'Donnell, who has posted about taking Mounjaro and called it "a life saver" after going down to a size 12, and Oprah Winfrey, who has said she uses a weight-loss drug "as a tool to manage not yo-yoing" rather than to hit a specific number on a scale ^[1]. Serena Williams has separately said a GLP-1 helped her blood sugar levels and joint comfort after she struggled to lose weight despite intense training ^[1][2]. Together, these accounts have shifted celebrity discussion of the drugs away from red-carpet appearance toward broader health framing, including diabetes risk, joint strain, and hormonal shifts ^[1][2].

Why it matters for patients

For women going through perimenopause or menopause, hearing a public figure describe hormonal-era weight and body changes as something outside their control, rather than a personal failing, may resonate. Williams's account echoes a pattern seen across other celebrity disclosures, where GLP-1 use is framed around metabolic health rather than appearance alone ^[1].

Still, patients should note that Mounjaro's approved use is for type 2 diabetes, and its role in menopause specifically has not been established through the sources reviewed here ^[1]. General GLP-1 research cited in one industry summary shows these drugs can lower a common blood sugar marker, HbA1c, by about 0.9% over six months and are linked to reduced risk of major cardiovascular events in people with type 2 diabetes, but this data is not specific to menopause or midlife weight change ^[2]. Anyone considering a GLP-1 for reasons related to menopause is dealing with an off-label or personalized medical decision that a doctor would need to evaluate based on individual health history.

Celebrity accounts, including Williams's, are also individual experiences and not clinical evidence. Reactions to these drugs vary widely; for example, podcast host Bunnie XO has described a severe negative mental health episode, including suicidal ideation, while on a GLP-1, which she attributed partly to her body's sensitivity to the medication ^[1]. That range of experience underscores that no single celebrity story reflects what any other individual patient might expect.

What happens next

It is not yet known from available reporting whether Williams's disclosure will be followed by additional detail on dosage, duration, or medical oversight, or whether regulators or manufacturers will address menopause-specific use of tirzepatide products going forward ^[1].